

**Cytokine and CAM – Interleukin-17 Agents
 Clinical Prior Authorization (PA) Request Form
 CT Medical Assistance Program
To Be Completed By Prescriber**

<u>Prescriber Information</u>	<u>Patient Information</u>
Prescriber's NPI:	Patient's Medicaid ID Number:
Prescriber Name:	Patient Name:
Prescriber Subspecialty:	Patient DOB:
Phone ()	Patient Current Weight:
Fax ()	Patient Primary ICD Diagnosis Code:
<u>Prescription Information</u>	
Drug, Strength, and Dosage Form Requested:	Frequency of Dosing:
<input type="checkbox"/> New therapy <input type="checkbox"/> Continuation	Quantity Requested:

<u>Preferred Agents:</u>	<u>Non-Preferred Agents:</u>
<u>PREFERRED IL12/IL23 AGENTS (listed for reference):</u> PYZCHIVA SYRINGE, SUBCUTANEOUS VIAL* SELARSDI SYRINGE, VIAL* STEQEYMA SYRINGE, VIAL* <u>PREFERRED TNFi AGENTS (listed for reference):</u> ADALIMUMAB-ADAZ PEN, SYRINGE ENBREL DISP SYRINGE, KIT, PEN ENBREL MINI CARTRIDGE, VIAL HADLIMA PUSHTOUCH, SYRINGE HUMIRA KIT, PEN INJECTION KIT INFLIXIMAB VIAL	BIMZELX AUTOINJECTOR, SYRINGE COSENTYX SENSOREADY PEN, SYRINGE TALTZ AUTOINJECTOR, SYRINGE

* Ustekinumab biosimilar

Clinical Information

(attach supporting documentation, **required**)

Note: Using samples to initiate therapy does not meet authorization requirements

1. Prescribed by or in consultation with a rheumatologist, dermatologist or any other specialist familiar with the treated disease state (or as appropriate for diagnosis)?	<input type="checkbox"/> Yes <input type="checkbox"/> No
---	--

<ul style="list-style-type: none"> ○ Please Specify: _____ 	
<p>2. Is patient using in combination with another targeted immunomodulator?</p> <ul style="list-style-type: none"> ○ Please specify alternate agent: _____ 	<input type="checkbox"/> Yes <input type="checkbox"/> No
<p>3. Does patient have active TB, or other active infection prior to initiation?</p> <ul style="list-style-type: none"> ○ Please specify infection: _____ 	<input type="checkbox"/> Yes <input type="checkbox"/> No
<p>4. For diagnosis of Active Ankylosing Spondylitis (AS), Moderate to Severe Hidradenitis Suppurativa (HS) or Active Non-radiographic Axial Spondyloarthritis (nr-axSpA): Patient has trialed and failed ONE tumor necrosis factor inhibitor (TNFi) for a minimum of 30 days OR documented adverse event/adverse drug reaction or contraindication</p> <ul style="list-style-type: none"> ▪ Preferred agent trialed: _____ ▪ Trial Dates: _____ ▪ Reason for Contraindication or Failure: _____ 	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A
<p>5. For diagnosis of Psoriatic Arthritis (PsA) or Moderate to Severe Plaque Psoriasis (PSO): Patient has trialed and failed ONE tumor necrosis factor inhibitor (TNFi) OR preferred ustekinumab biosimilar for a minimum of 30 days OR documented adverse event/adverse drug reaction or contraindication</p> <ul style="list-style-type: none"> ▪ Preferred agent trialed: _____ ▪ Trial Dates: _____ ▪ Reason for Contraindication or Failure: _____ 	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A

For Initial Approval:
Medication Requested and Documented diagnosis of ONE of the following:
(attach supporting documentation, required)

<p><u>Bimzelx (bimekizumab-bkzx):</u></p> <ul style="list-style-type: none"> ● Patient has a documented diagnosis of ONE of the following: <ul style="list-style-type: none"> ○ Active Ankylosing Spondylitis (AS) (18+ years of age) ○ Moderate to Severe Hidradenitis Suppurativa (HS) (18+ years of age) ○ Active Non-radiographic Axial Spondyloarthritis (nr-axSpA) (18+ years of age) ○ Active Psoriatic Arthritis (PsA) (18+ years of age) ○ Moderate to Severe Plaque Psoriasis (PSO) (18+ years of age) and is a candidate for systemic therapy or phototherapy AND ● Failure to achieve the desired therapeutic outcome following a trial of at least ONE preferred 	<input type="checkbox"/> Yes <input type="checkbox"/> No
---	--

<p>agent appropriate for the specified indication (as outlined above in Questions 4 and 5 of the Clinical Information section) AND</p> <ul style="list-style-type: none"> • <u>For Active Non-radiographic Axial Spondyloarthritis (nr-axSpA) Diagnosis:</u> Supporting documentation of objective signs of inflammation (e.g. elevated C-reactive protein, evidence of sacroiliitis on MRI) are ATTACHED 	
<p><u>Cosentyx (secukinumab):</u></p> <ul style="list-style-type: none"> • Patient has a documented diagnosis of Active Enthesitis-related Arthritis (ERA) (4+ years of age) OR • ONE of the following: <ul style="list-style-type: none"> ▪ Active Ankylosing Spondylitis (AS) (18+ years of age) ▪ Moderate to Severe Hidradenitis Suppurativa (HS) (12+ years of age) ▪ Active Non-radiographic Axial Spondyloarthritis (nr-axSpA) (18+ years of age) ▪ Active Psoriatic Arthritis (PsA) (2+ years of age) ▪ Moderate to Severe Plaque Psoriasis (PSO) (6+ years of age) and is a candidate for systemic therapy or phototherapy AND ○ Failure to achieve the desired therapeutic outcome following a trial of at least ONE preferred agent appropriate for the specified indication (as outlined above in Questions 4 and 5 of the Clinical Information section) AND ○ <u>For Active Non-radiographic Axial Spondyloarthritis (nr-axSpA) Diagnosis:</u> Supporting documentation of objective signs of inflammation (e.g. elevated C-reactive protein, evidence of sacroiliitis on MRI) are ATTACHED 	<input type="checkbox"/> Yes <input type="checkbox"/> No
<p><u>Taltz (ixekizumab):</u></p> <ul style="list-style-type: none"> • Patient has a documented diagnosis of ONE of the following: <ul style="list-style-type: none"> ○ Active Ankylosing Spondylitis (AS) (18+ years of age) ○ Active Non-radiographic Axial Spondyloarthritis (nr-axSpA) (18+ years of age) ○ Active Psoriatic Arthritis (PsA) (18+ years of age) ○ Moderate to Severe Plaque Psoriasis (PSO) (6+ years of age) and is a candidate for systemic therapy or phototherapy AND • Failure to achieve the desired therapeutic outcome following a trial of at least ONE preferred agent appropriate for the specified indication (as outlined above in Questions 4 and 5 of the Clinical Information section) AND 	<input type="checkbox"/> Yes <input type="checkbox"/> No

<ul style="list-style-type: none"> • <u>For Active Non-radiographic Axial Spondyloarthritis (nr-axSpA) Diagnosis:</u> Supporting documentation of objective signs of inflammation (e.g. elevated C-reactive protein, evidence of sacroiliitis on MRI) are ATTACHED 	
---	--

Renewal Information

(attach supporting documentation, **required**)

Note: Using samples to initiate therapy does not meet renewal authorization requirements

<ul style="list-style-type: none"> • Has the patient previously met the required criteria set forth in Initial Approval Section above? <ul style="list-style-type: none"> ○ Previous Approved Prior Authorization Number: _____ ○ Approval Dates: _____ 	<input type="checkbox"/> Yes <input type="checkbox"/> No
<ul style="list-style-type: none"> • Patients' clinical response to treatment and ongoing safety has been documented and monitored 	<input type="checkbox"/> Yes <input type="checkbox"/> No
<ul style="list-style-type: none"> • Prescriber attests that the patient has a continued need for therapy and is compliant with current regimen 	<input type="checkbox"/> Yes <input type="checkbox"/> No

Please Note: Pharmacies should not be contacting prescribers to provide pre-signed PA forms or submitting pre-signed forms for PA, nor should prescribing providers be requesting that pharmacies perform PA activities for them. PA requests must originate from the prescriber, and only the prescriber should sign the form at the time of PA submission.

I certify that documentation is maintained in my files and the information given is true and accurate for the medication requested, subject to penalty under section 17b-99 of the Connecticut General Statutes and sections 17-83k-1- to 17-83k-7, inclusive, of the Regulations of Connecticut State Agencies. I certify that the above-referenced member is a patient under my clinic's/practice's ongoing care. I understand that a prior authorization may not exceed one (1) year from the date of fill for non- controlled medications. Authorizations for Early Refill Requests are valid one time only.

Prescriber Signature*: _____ **Date:** _____

*** Mandatory (others may not sign for prescriber). In accordance with federal law, prescribers must be enrolled in the Connecticut Medical Assistance Program (CMAP). CMAP will not pay for prescriptions written by a non-enrolled provider.**

This form (and attachments) contains protected health information (PHI) for Gainwell Technologies and is covered by the Electronic Communications Privacy Act, 18 U.S.C. § 2510-2521 and the Standards for Privacy of Individually Identifiable Health Information, 45 CFR Parts 160 and 164, which is intended only for the use of prior authorization. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited. Any unintended recipient should contact Gainwell Technologies by telephone at (860) 255-3900 or by e-mail immediately and destroy the original message.